Therapeutic Asset Ratings

3,272 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Fallopian Tube Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ioc Immune System Disorder	National Cancer Institute (NCI)	P2	CCC (53)
Ioc Lymphoproliferative Syndrome	National Cancer Institute (NCI)	P2	CCC (53)
Ioc Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Urinary Bladder Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Breast Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Cervical Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Colon Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Endometrial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Gastric Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Hematopoietic And Lymphoid Cell Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Lung Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Female Reproductive Organ Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Uterine Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Ovarian Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Prostate Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)

Showing 1451 to 1475 of 3,272 assets

PreviousPage 59 of 131Next